問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of Infectious Disease

Division of Pediatrics

Division of General Internal Medicine

Division of Rheumatology

更新時間:2024-06-12

傅彬貴Fu, Pin-Kuei
  • Principal Investigator
  • Clinical Trial Experience (year)
  • yetquen@gmail.com

篩選

List

45Cases

2023-10-16 - 2027-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2025-01-01 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2025-02-21 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2026-02-20 - 2031-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-06-16 - 2029-09-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2014-09-01 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-12-01 - 2017-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia
  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin(aerubumab,AR-105)

Participate Sites
11Sites

Terminated10Sites

2016-08-01 - 2018-12-31

Phase III

A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
  • Condition/Disease

    carbapenem-resistant Gram-negative bacterial infections

  • Test Drug

    S-649266

Participate Sites
7Sites

Terminated7Sites

1 2 3 4 5